GlassScriptPhysician profile
Allie C Toth
NPI 1851881866
$5,931.90
in general payments reported to CMS, 2019-2025
11 companies · $1,513 in 2025
The $1,513 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,123 · 2023: $1,035 · 2024: $2,261 · 2025: $1,513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,880 · Food and Beverage: $1,404 · Consulting Fee: $525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,879.92 |
| Food and Beverage | $1,404.06 |
| Consulting Fee | $525.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,388.60 | 2022-2025 | Vercise, General - Therapies, General - Dbs |
| Medtronic, INC. | $1,197.36 | 2022-2023 | Percept PC Brainsense, Activa PC |
| Amneal Pharmaceuticals LLC | $525.00 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $205.04 | 2024-2025 | Austedo Xr, Austedo Xr |
| Acadia Pharmaceuticals INC | $167.36 | 2022-2025 | Nuplazid |
| Acorda Therapeutics, INC | $152.64 | 2022-2023 | Inbrija |
| Neurocrine Biosciences, INC. | $130.70 | 2023 | |
| Abbvie INC. | $98.95 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.92 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $22.93 | 2023 | Nuedexta |
| Ucb, INC. | $13.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allie Toth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.